ENDRA Life Sciences Amends Merger Terms with ASP Isotopes to Streamline Governance and Finance

Key Facts

1ENDRA Life Sciences amended its merger agreement to remove proposed classified-board and supermajority-vote provisions.

2New terms include a minimum cash closing requirement of approximately $3.8 million and an increase in Renergen’s borrowing capacity from ASPI to $200 million.

ENDRA Life Sciences amended its merger agreement with ASP Isotopes and other partners to remove proposed classified-board and supermajority-vote provisions. Stock Titan reported that the new terms establish a minimum cash closing requirement of approximately $3.8 million and increase Renergen’s borrowing capacity from ASPI to $200 million.

NDRA closed at $5.88 on October 1, 2026, while ASPI closed at $2.70 on the same day. These governance and financial revisions aim to streamline the merger process, with the amendments also removing certain beneficial-ownership limits on warrant exercises for ASP affiliates.